Monoclonal antibodies interfering with the PD-1/PD-L1 pathway inhibit T cell exhaustion in the tumor microenvironment and could therefore also enhance the anti-tumor effect of T cells induced by DC-based immunotherapy. The gene discussed is CD274; the disease is neoplasm.